- Home
- TERN vs NAMS Comparison
TERN vs NAMS Comparison
Compare TERN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TERN | NAMS |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.6B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TERN | NAMS |
|---|---|---|
| Price | $52.97 | $35.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $45.22 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 3.1M | 1.5M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $16.79 |
| 52 Week High | $53.19 | $42.21 |
Technical Indicators
Market Signals| Indicator | TERN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 74.51 | 54.59 |
| Support Level | $52.42 | $34.05 |
| Resistance Level | $53.19 | $37.25 |
| Average True Range (ATR) | 0.07 | 2.43 |
| MACD | -0.31 | 0.03 |
| Stochastic Oscillator | 97.30 | 47.81 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.